RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.9100
-0.0900 (-9.00%)
At close: Apr 3, 2025, 4:00 PM
0.9232
+0.0132 (1.45%)
After-hours: Apr 3, 2025, 5:10 PM EDT
RenovoRx Revenue
In the year 2024, RenovoRx had annual revenue of $43.00K. RenovoRx had revenue of $43.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$43.00K
Revenue Growth
n/a
P/S Ratio
827.10
Revenue / Employee
$5,375
Employees
8
Market Cap
32.36M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RNXT News
- 2 days ago - RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - Business Wire
- 6 days ago - RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting - Business Wire
- 8 days ago - RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting - Business Wire
- 14 days ago - RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET - Business Wire
- 15 days ago - RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 - Business Wire
- 5 weeks ago - RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders - Business Wire
- 7 weeks ago - RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery - Business Wire
- 7 weeks ago - RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire